Intellia Therapeutics Inc (NTLA) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Intellia Therapeutics Inc   (NASDAQ: NTLA)


Intellia Therapeutics Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Intellia Therapeutics Inc's ROI in the second quarter of 2026?
Intellia Therapeutics Inc recorded a cumulative net loss of $-400 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -52.8%.

Within the Healthcare sector 462 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3661 to 3739.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Investment Change TTM 26.55 % -60.44 % -58.68 % -52.06 % -47.78 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 778 682 738 832 -627
Return On Investment (TTM) -52.8 % -97.13 % -90.89 % -82.63 % -
NTLA's Overall Ranking # 3739 # 3661 # 2809 # 2240 # 3048
Seq. Investment Change TTM 86.45 % -10.53 % -15.84 % -9.86 % -41.71 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -400 -395 -413 -446 -480

NTLA Company Profile >> Back to NTLA Roi Comparisons >> See Annual NTLA Return On Investment



Return On Investment NTLA's Ranking
Within: No.
Industry # 8
Sector # 463
Overall # 3739

Return On Investment Statistics
High Average Low
-12.79 %
-35.59 %
-52.8 %
(Dec 31 2016)   (Jun 30 2026)



  News about Intellia Therapeutics Inc Return on Investment ROI

Intellias CRISPR Breakthrough Offers Hope in Treating Transthyretin Amyloidosis,

November 16, 2024

In a groundbreaking advancement that could redefine the future of genetic medicine, Intellia Therapeutics, Inc. a prominent leader in CRISPR-based therapies, has recently reported promising results from its Phase 1 clinical study of nexiguran ziclumeran, also referred to as NTLA-2001. This novel therapy marks a significant step toward a one-time treatment solution for transthyretin (ATTR) amyloidosis a rare and life-threatening disease characterized by the accumulation of misfolded transthyretin proteins, leading to a spectrum of debilitating symptoms, including neuropathy and cardiomyopathy.On November 16, 2024, Intellia announced these pivotal findings, which represent a beacon of hope not only for patients grappling with ATTR amyloidosis but also for the broader field of genome editing therapies. The study, conducted in collaboration with Regeneron Pharmaceuticals, is part of an ambitious multi-target collaboration aimed at utilizing CRISPR/Cas9 technology to address diseases at the genetic level.

Breaking New Ground in Gene Editing Promising Results from Nexiguran Ziclumeran for ATTR Amyloidosis

October 1, 2024

Intellia Therapeutics has embarked on a significant journey in the realm of gene editing with its lead investigational therapy, nexiguran ziclumeran (nex-z, also known as NTLA-2001). Aimed at treating transthyretin (ATTR) amyloidosis, a debilitating condition often resulting in severe cardiac complications, this novel CRISPR-based therapeutic demonstrates the potential to revolutionize treatment paradigms. Recent interim data from an ongoing Phase 1 study set to unfold at the upcoming American Heart Association (AHA) Scientific Sessions shines a much-anticipated spotlight on its safety and early efficacy. Transthyretin amyloidosis is increasingly recognized as an underdiagnosed condition precipitating significant morbidity and mortality, particularly in the form of cardiomyopathy (ATTR-CM). Traditional therapeutic options have been limited, necessitating innovative approaches that can enhance both disease management and patient outcomes. The introduction of nexiguran ziclumeran heralds a transformative approach that leverages CRISPR gene-editing technology to target the underlying pathophysiology of ATTR amyloidosis.





Financial Statements
Intellia Therapeutics Inc's II. Quarter Investments $ 778 Millions NTLA's Balance sheet
Intellia Therapeutics Inc's II. Quarter Income $ -107 Millions Quarterly NTLA's Income Statement
NTLA's Income by Division See NTLA's Income by Division


NTLA Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 738 1,080 1,186 1,236 1,169
Y / Y Investment Growth -31.65 % -8.91 % -4.03 % 5.73 % 90.93 %
Net Income in Millions -413 -519 -481 -474 -268
Y / Y Net Income Growth - - - - -
Annual Return On Investment -55.9 % -48.05 % -40.58 % -38.38 % -22.92 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
NTLA's Roi Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for NTLA's Competitors
Subscribers only: Roi for Intellia Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for NTLA's Customers

Other Ratios
NTLA's Roa NTLA's Inventory Turnover Ratio NTLA's Growth Rates NTLA's Dividend Statistics
NTLA's Profitability Ratios NTLA's Asset Turnover Ratio NTLA's Dividend Growth
NTLA's Roe NTLA's Valuation Ratios NTLA's Financial Strength Ratios NTLA's Dividend Payout Ratio



Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector ROI

Date modified: 2026-09-26T07:28:20+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.